Tag Archives: R&D
By Guest Blogger | Published: September 25, 2012
There’s a lot of talk today about “open innovation” in business and research forums—but what exactly does it mean? How does open innovation as a concept apply to the pharma sector? Does it signal a change in the way pharma companies approach research and innovation? Roy F. Waldron reports. There are a number of highly innovative [...]
By William Looney | Published: August 8, 2012
Today’s big product story — the apparent end to a decade-long drought in the drug development pipeline — is the prep stage for tomorrow’s big policy question: are industry R&D priorities in synch with the changing burden of disease?
By Ben Comer | Published: June 11, 2012
Following his keynote address last week at the Financial Times US Healthcare and Life Sciences Conference in New York, Eli Lilly CEO John Lechleiter huddled into a corridor to speak with PharmExec about his agenda as incoming chairman of PhRMA, and how to fix innovation.
By Ben Comer | Published: May 21, 2012
Recognizing that traditional market forces – namely incentives related to intellectual property and a steady demand for products – have failed in developing countries, the World Health Organization (WHO) asked a member state-nominated group to come up with ways to fund R&D and pay for the treatment of neglected diseases in the world’s poorest nations. [...]
By Guest Blogger | Published: February 13, 2012
by Joe DiMasi, director of economic analysis, Tufts Center for the Study of Drug Development William Looney’s posting for this blog, “Calculating the Cost of R&D: Defending Tufts Research” (January 11, 2012), raises a number of interesting and important points. Both the posting and the working paper by F.M. Scherer on which the posting was based, [...]